Core Viewpoint - Hangzhou Deshi Biotechnology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International as the sole sponsor, indicating its intent to go public after a previous attempt in June 2025 [1] Company Overview - Deshi Biotechnology is focused on developing medical imaging products and services, aiming to enhance diagnostic efficiency and service quality [1] - The company has a diversified product portfolio that includes: - Six medical imaging software products, which consist of one core product AI AutoVision in the registration stage, one commercial product AutoVision, and four candidates in the preclinical stage [1] - Three commercialized medical devices [1] - Four main reagents and consumables [1] - Additionally, Deshi Biotechnology offers technology licensing services to meet the diverse needs of various medical institutions, academic research institutions, and regional medical organizations [1]
新股消息 | 德适生物再度递表港交所
智通财经网·2026-01-06 22:23